GlassScriptPhysician profile
Amanda Hayes
NPI 1073230025
$1,769.08
in general payments reported to CMS, 2019-2025
13 companies · $746 in 2025
The $746 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $140 · 2023: $440 · 2024: $443 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $360.20 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $307.90 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $305.71 | 2024-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $282.50 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Medtronic, INC. | $103.62 | 2025 | Venaseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.79 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $80.12 | 2023 | |
| Astellas Pharma US INC | $78.30 | 2024 | Veozah |
| Exact Sciences Corporation | $60.36 | 2023-2025 | Cologuard Collection Kit |
| Recor Medical INC | $40.21 | 2025 | Paradise Ultrasound Renal Denervation System |
| Gilead Sciences, INC. | $34.67 | 2025 | |
| Pfizer INC. | $17.41 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.29 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.